Medical Care
Carta Healthcare Buys Realyze Intelligence for AI Expansion
2024-12-11
Carta Healthcare, a pioneer in AI technology for data abstraction, has made a significant move by acquiring Realyze Intelligence. This portfolio company of UPMC Enterprises brings with it a wealth of capabilities and a shared vision to revolutionize healthcare through the power of AI.

Uniting AI for Faster Healthcare Insights

Expanding Combined AI Platforms

The acquisition aims to combine the strengths of both companies. Realyze Intelligence's platform utilizes AI to match patients to clinical trials, expediting research and reducing costs. It examines structured and unstructured data in EHRs to identify ideal patients, while its clinician-trained AI can assemble suitable cohorts in seconds. Carta Healthcare's platform, on the other hand, applies AI to structured and unstructured data to reduce the time and price for data abstraction. Together, they anticipate that their combined technologies' "powerful" automation will offer faster insights and significantly reduce labor demands for various healthcare programs.

For example, in oncology, cardiovascular health, and other specialty areas, the combined platforms have the potential to expand the feasibility of trials and research while increasing data abstraction with expert clinician oversight. This is a major step forward in leveraging AI to improve healthcare outcomes.

CEO Perspectives on the Importance of Data

Brent Dover, CEO of Carta Healthcare, emphasizes the significance of data in healthcare. He believes that data is the single most important ingredient for improving care practices and patient outcomes. From clinical trials to clinical registries, clinicians face vast amounts of data filled with valuable information. Realyze Intelligence's ability to use clinician-trained AI and a human-in-the-loop approach aligns with Carta Healthcare's mission to maximize insights from clinical data.

This shared vision is driving the collaboration and innovation between the two companies. By combining their expertise, they are poised to make a significant impact on the healthcare industry.

Addressing Challenges in Clinical Trials

Aaron Brauser, founder and CEO of Realyze Intelligence, highlights the challenges faced by health systems and pharmaceutical companies in identifying and enrolling patients for clinical trials. The process is costly, labor-intensive, and time-consuming. However, with high-quality, timely data from EHRs and other systems, Realyze Intelligence aims to revolutionize clinical trial matching and reuse the data to enhance research, optimize care pathways, and improve patient outcomes.

For instance, by leveraging AI, they can quickly identify eligible patients and assemble suitable cohorts, saving valuable time and resources. This not only benefits the patients but also accelerates the progress of medical research.

Recent Developments and Funding

In 2023, Carta Healthcare closed a $25 million series B financing round, with additional investments from Memorial Hermann Health System and UnityPoint Health. This follows a $20 million Series B financing round in 2022, which included investors like Paramark Ventures, Frist Cressey Ventures, American College of Cardiology, Asset Management Ventures, CU Healthcare Innovation Fund, Mass General Brigham, Maverick Ventures Investment Fund, and Storm Ventures.

In 2022, Carta Healthcare also became a certified software vendor for the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry. This further showcases their commitment to advancing healthcare through technology.

Moreover, in April, researchers at Memorial Sloan Kettering Cancer Center applied machine learning and large language models to augment the manual curation of cancer data elements using the Realyze Intelligence platform. In February, Realyze Intelligence earned a position among the inaugural class of start-up companies selected for the CancerX Startup Accelerator, part of the Biden administration's Cancer Moonshot program.

These recent achievements demonstrate the growing impact and potential of AI in healthcare and the importance of collaborations like the one between Carta Healthcare and Realyze Intelligence.

Claire Grisham Joins Saint Francis Clinic Dexter in 2024
2024-12-11
December 11, 2024 marks a significant addition to Saint Francis Healthcare System. Claire Grisham, an FNP-C, has joined Saint Francis Clinic Dexter, a renowned Saint Francis Medical Partner. Her medical education was completed in 2023 at Walden University in Minneapolis, MN. With board certification from the American Academy of Nurse Practitioners Certification Program, she specializes in primary care and urgent care. Saint Francis Clinic – Dexter is conveniently located at 1212 Saint Francis Drive, Dexter, MO. For more information, one can visit Grisham’s online profile or give a call to Saint Francis Clinic Dexter at 573-614-3600.

Why Claire Grisham's Joining is a Big Deal

Claire Grisham's arrival at Saint Francis Clinic Dexter brings a wealth of expertise and care. Her specialized skills in primary and urgent care will undoubtedly enhance the services offered at the clinic. With her board certification, patients can have confidence in the quality of care she provides. The fact that she graduated from a prestigious institution like Walden University further adds to her credibility.

Moreover, the location of the clinic at 1212 Saint Francis Drive in Dexter, MO makes it easily accessible for the local community. This ensures that residents can receive timely and quality medical attention without having to travel long distances.

Primary Care with Claire Grisham

Claire Grisham's focus on primary care is crucial for the overall health of patients. She takes the time to understand each patient's unique needs and provides comprehensive care. From routine check-ups to managing chronic conditions, she is dedicated to ensuring the well-being of her patients.

Her approach is patient-centered, making patients feel comfortable and at ease during their visits. She builds strong relationships with her patients, which helps in providing better care and improving health outcomes.

Urgent Care Services Offered

In addition to primary care, Claire Grisham also offers urgent care services. In case of sudden illnesses or injuries, patients can rely on her to provide prompt and effective treatment. Her expertise in this area ensures that patients receive the care they need quickly, minimizing the risk of complications.

The availability of urgent care services at Saint Francis Clinic Dexter gives patients peace of mind, knowing that they have a reliable source of medical help when needed the most.

See More
Enhancing Food Allergen Testing with Neogen's Solutions
2024-12-11
In Australia, the most prevalent reason for costly product recalls is the presence of undeclared food allergens. Recent data reveals that over the five years up to 2023, these allergens accounted for a significant 44 percent of the 438 recalls coordinated by FSANZ. Hasitha Perera, Neogen's Food Safety Business sales manager for Australia and New Zealand, has noticed a growing interest in rapid allergen testing solutions. He emphasizes the increasing prevalence of food allergies worldwide and the serious potential consequences for consumers. Governments have implemented measures like mandatory labelling requirements to enhance safeguards, making it crucial for producers and importers to be aware of all risks associated with their products. In February 2024, new allergen labelling requirements came into effect in Australia, aiming to assist consumers in making safer choices by mandating the declaration of 23 foods and ingredients.

Cost Implications of Product Recalls

In addition to the public risk, product recalls can be extremely costly and time-consuming. Perera highlights the importance of producers understanding where allergens could enter their production line and being alerted promptly. Diagnostic allergen tests offer a valuable method for determining if a product has been subjected to cross-contact and for investigating how and when it occurred. These tests can be used on raw materials before production or on equipment and products at various points during the process to identify and eliminate possible risks.

Neogen's Rapid Qualitative Testing Solutions

Neogen is a leader in food allergen diagnostic tests and provides both rapid qualitative and fully quantitative testing solutions. Screening tests like their Reveal product line are simple, easy to use, and provide quick results within just five minutes. These devices feature an overload line to prevent the hook effect and false negatives. They are designed to determine the presence or absence of a target allergen with ease.

Neogen's Quantitative Testing Solutions

Quantifying tests, such as Neogen's Veratox, utilize ELISA technology to determine the exact parts per million (ppm) of a target allergen. Veratox can yield results in just 30 minutes of testing time. The process can be further streamlined with the StatFax 4700 plate reader, which is designed to read and calculate the results of Veratox assays automatically.

Neogen's Enhanced Sensitivity Testing

More recently, Neogen introduced Veratox VIP, which offers the same ease-of-use and 30-minute time-to-result as standard Veratox allergen tests but with significantly enhanced sensitivity. VIP allows users to detect extremely low levels of target allergens in a wide variety of sample types, including heat-processed and complex samples. This provides producers with a more comprehensive tool for managing allergen risks.

Unparalleled Support from Neogen

As a global company with a strong local presence in Australia and New Zealand, Neogen offers unparalleled support to its customers through a dedicated network of scientists and technical experts. Their extensive range of food quality and safety products is designed to help businesses make critical decisions confidently and quickly, improving efficiency and adding value. To learn more about allergen testing or their expanded food quality and safety product range, visit neogenaustralasia.com.au.
See More